

101-001
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



09 JUL. 2004



(43) International Publication Date
17 July 2003 (17.07.2003)

PCT

(10) International Publication Number
WO 03/057684 A1

(51) International Patent Classification⁷: C07D 309/06

Hansoljugong 5-danji 511-1005, Jeongja-dong, Bundang-gu, 463-911 Seongnam-si, Kyungki-do (KR). **LEE, Hoechul** [KR/KR]; Sinjeongmaeul 1-danji 111-1504, #1065, Poongdukcheon-ri, Suji-eup, 449-840 Yongin-si, Kyungki-do (KR). **LEE, Gwansun** [KR/KR]; Keukdong Apt. 2-806, Karak-dong, Songpa-gu, 138-160 Seoul (KR). **CHANG, Youngkil** [KR/KR]; #34-4, Samjeon-dong, Songpa-gu, 138-180 Seoul (KR).

(21) International Application Number: PCT/KR02/02434

(74) Agents: **JANG, Seongku** et al.; 17th Fl., KEC Building, #275-7 Yangjae-dong, Seocho-ku, 137-130 Seoul (KR).

(22) International Filing Date:
26 December 2002 (26.12.2002)

(81) Designated States (national): AU, CA, CN, HU, IN, JP, US.

(25) Filing Language: English

(84) Designated States (regional): European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR).

(26) Publication Language: English

Published:

— with international search report

(30) Priority Data:
10-2002-0001118 9 January 2002 (09.01.2002) KR

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(71) Applicant (for all designated States except US): **HANMI PHARM. CO., LTD.** [KR/KR]; #893-5, Hajeo-ri, Paltan-myeon, Hwaseong-gun, 445-910 Kyungki-do (KR).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **LEE, Jaeheon** [KR/KR]; Sangrok Apt. 611-1201, #1028, Poongdukcheon-ri, Suji-eup, 449-840 Yongin-si, Kyungki-do (KR). **HA, Taehee** [KR/KR]; Sinnamusil 512-1504, #964-5, Youngtong-dong, Paldal-gu, 442-470 Suwon-si, Kyungki-do (KR). **PARK, Chulhyun** [KR/KR];



WO 03/057684 A1

(54) Title: PROCESS FOR THE PREPARATION OF SIMVASTATIN

(57) Abstract: Highly pure simvastatin can be prepared economically in a high yield using the method comprising the steps of treating lovastatin with potassium hydroxide dissolved in a mixture of water and methanol to obtain a triol acid; relactonizing the triol acid, and protecting the hydroxy group on the lactone ring; and acylating the resulting compound with 2,2-dimethylbutyryl chloride or 2,2-dimethylbutyryl bromide in the presence of an acylation catalyst in an organic solvent, followed by removing the silyl protecting group on the lactone ring to obtain simvastatin.

PROCESS FOR THE PREPARATION OF SIMVASTATIN


Field of the Invention

5 The present invention relates to a low-cost process for preparing high-purity simvastatin in a high yield.

Background of the Invention


10 Some hexahydroronaphthalene derivatives, e.g., lovastatin, atorvastatin, cerivastatin and simvastatin, are potent inhibitors of HMG-CoA(3-hydroxy-3-methylglutaryl CoA) reductase, the enzyme which controls the biosynthesis of cholesterol, and therefore, used widely for the treatment of hyperlipidemia, hypercholesterolemia, and others. In particular, simvastatin of formula (I) is
15 favored over other hexahydroronaphthalene derivatives because of the absence of adverse side effects and its high absorbability in the stomach. Also, it has been reported that simvastatin prevents and reduces the risk of Alzheimer's disease(AD) by retarding the production of Ab42, β -amyloid protein related to the outbreak of AD.

20



The synthesis of simvastatin from lovastatin have been conducted based mainly on one of the two following methods.


U.S. Patent No. 5,393,893, U.S. Patent No. 4,582,915, U.S. Patent No. 5,763,646, U.S. Patent No. 5,763,653, EP Patent No. 299,656 and International 5 Patent Publication No. WO 99/45003 disclose a method of preparing simvastatin of formula (I) by way of direct methylation of the 8'-methylbutyryloxy side chain of lovastatin of formula (II) using a methyl halide in the presence of a metal amide base. However, this method has the disadvantage that the C-methylation step has to be carried out at an extremely low temperatures(-75 to -30 °C) using a strong 10 base under anhydrous condition which is difficult to handle in mass production.



Another method disclosed in U.S. Patent No. 4,444,784 is represented 15 by Scheme 1. First, lovastatin of formula (II) is hydrolyzed with an excessive amount of lithium hydroxide to remove the 2-methylbutyryl side chain and to simultaneously open its 6-membered lactone ring to produce the triol acid of formula (III). The triol acid compound of formula (III) is then heated to obtain the diol lactone of formula (IV). The hydroxy group on the lactone ring of the 20 diol lactone is protected to obtain the tert-butyldimethylsilyl ether of formula (V) and then the hydroxy group at C-8 of the hexahydronaphthalene ring system is acylated with 2,2-dimethylbutyric acid in the presence of dicyclohexyl

carbodiimide, or 2,2-dimethyl chloride to produce the compound of formula (VI). The t-butyldimethylsilyl protecting group of the compound of formula (VI) is then removed in the final step using tetrabutylammonium fluoride to produce simvastatin of formula (I):

5

Scheme 1

However, this method requires a high temperature and 56 hours of long
10 reaction time in the hydrolysis and acylation steps, which leads to a number of undesired side products, causing low yield and purity of the final product.

In addition, Korean Publication No. 2000-15179 discloses a modification of the method of reaction scheme 1, wherein t-BuOK is used in the hydrolysis step, and acyloxy triphenylphosphonium salts, in the acylation step. However, this




method requires the use of t-BuOK which is expensive and causes unwanted side reaction and gives low yield, and excessively large amounts of reagents such as 2,2-dimethyl butanoic acid, triphenyl phosphine and N-bromosuccinimide, the unreacted reagents being removed by complicated purification procedures. Thus,
5 like the other methods, this method is also not suitable for mass production.

Summary of the Invention


Accordingly, it is a primary object of the present invention to provide
10 an improved process for preparing simvastatin of high-purity in a high yield, which can be advantageously used for mass production of simvastatin.

In accordance with one aspect of the present invention, there is provided a method of preparing simvastatin of formula (I) comprising the steps of:

- 15 (a) treating lovastatin of formula (II) with potassium hydroxide dissolved in a mixture of water and methanol to obtain the compound of formula (III);
(b) relactonizing the compound of formula (III), and protecting the hydroxy group on the lactone ring to obtain the compound of formula (V); and
(c) acylating the compound of formula (V) with 2,2-dimethylbutyryl chloride or
- 20 2,2-dimethylbutyryl bromide in the presence of an acylation catalyst which is a compound of formula (VII) or a compound of formula (VIII) in an organic solvent, followed by removing the silyl protecting group on the lactone ring to obtain simvastatin of formula (I).



5





5 wherein R^1 is C_{1-20} alkyl or phenyl; R^2 is C_{1-20} alkyl, phenyl, or benzyl; and X is Br or I.

Detailed Description of the Invention

10 The method of the present invention makes it possible to prepare highly pure simvastatin in a high yield under a mild condition, by using potassium hydroxide dissolved in a mixture of water and methanol in the hydrolysis step (a), and an acylation catalyst such as quaternary ammonium halides and quaternary phosphonium halides in the acylation step (c).

15 The method of the present invention is described in detail as follows:

Step (a)

Potassium hydroxide is employed in an amount ranging from 5 to 15 equivalents, preferably from 8 to 12 equivalents, based on the amount of 20 lovastatin of formula (II).

Water and methanol may be used in a ratio(v:v) of 1:2 to 1:20, preferably 1:4 to 1:12, and the water and methanol mixture may be used in an amount of 1 to 8 ml, preferably 4 to 6 ml, per 1 g of potassium hydroxide.

The hydrolysis step may be performed at a temperature ranging from 20 25 to 80 °C, preferably from 50 to 70 °C, for about 5 to 12 hours, to give the compound of formula (III) as a white solid having a purity of at least 98%, in a high yield of at least 95%, 10% higher than that of the 56 hours long hydrolysis

step with t-BuOK of the conventional method.

Step (b)

This step may be performed modifying the conventional method(U.S. Patent No. 4,444,784) to give the compound of formula (V) having a purity of at least 98% in a yield of 90% or higher.

Step (c)

In this process, the compound of formula (V) prepared in step (b) may be refluxed together with 2,2-dimethylbutyryl halide in the presence of an acylation catalyst such as a quaternary ammonium halide or a quaternary phosphonium halide in benzene while azeotropically removing water using a Dean-stark trap, to give a compound of formula (VI) having a purity of at least 98% in a yield of 95% or higher. The acylation catalyst facilitates the completion of the reaction within 6 to 8 hours, which should be compared with 3 to 4 days required in the conventional method.

The quaternary ammonium halide compound which may be used in the present invention includes benzyltri-n-butylammonium bromide, benzyltriethylammonium bromide, n-decytrimethylammonium bromide, n-dodecytrimethylammonium bromide, n-octyltrimethylammonium bromide, phenyltrimethylammonium bromide, tetra-n-butylammonium bromide, tetraethylammonium bromide, tetra-n-hexylammonium bromide, tetramethylammonium bromide, tetra-n-propylammonium bromide, benzyltriethylammonium iodide, phenyltriethylammonium iodide, phenyltrimethylammonium iodide, tetra-n-butylammonium iodide, tetra-n-heptylammonium iodide, tetra-n-hexylammonium iodide, tetra-n-octylammonium iodide, tetra-n-propylammonium iodide and tetramethylammonium iodide, etc.,

among which benzyltri-n-butylammonium bromide and tetra-n-butylammonium bromide are most preferred.

Further, the quaternary phosphonium halide compound which may be used in the present invention includes benzyltriphenylphosphonium bromide, n-
5 butyltriphenylphosphonium bromide, methyltriphenylphosphonium bromide, ethyltriphenylphosphonium bromide, n-heptyltriphenylphosphonium bromide, n-hexyltriphenylphosphonium bromide, n-propyltriphenylphosphonium bromide, tetra-n-butylphosphonium bromide, tetra-n-octylphosphonium bromide,
10 tetraphenylphosphonium bromide, tetraphenylphosphonium iodide and methyltriphenylphosphonium iodide, etc., among which tetra-n-butylphosphonium bromide is most preferred.

The quaternary ammonium halide or quaternary phosphonium halide may be used in an amount ranging from 0.5 to 3.0 equivalents, preferably from 0.8 to 1.5 equivalents, based on the amount of the compound of formula (V).

2,2-dimethylbutyryl chloride or 2,2-dimethylbutyryl bromide may be used in an amount ranging from 1 to 3 equivalents, preferably from 1.3 to 1.8 equivalents, based on the amount of the compound of formula (V).

Also, pyridine may be added to the above reaction mixture to neutralize HCl produced in an amount ranging from 2 to 4 equivalents, based on the amount
20 of the compound of formula (V).

Subsequently, the removal of the t-butyldimethylsilyl protecting group of the compound (VI) may be carried out by the conventional method(U.S. Patent No. 4,444,784) to obtain simvastatin of formula (I) having a purity of at least 99% in a high yield of 90% or higher.

As described above, according to the present invention, highly pure simvastatin can be obtained in a high yield at a low production cost.
25

The following Examples are given for the purpose of illustration only,

and are not intended to limit the scope of the invention.

Example

- 5 Example 1: Preparation of 7-[1',2',6',7',8',8a'(R)-hexahydro-2'(S),6'(R)-dimethyl-8'(S)-hydroxy-1'(S)-naphthyl]-3(R),5(R)-dihydroxy heptanoic acid (the compound of formula (III))

10 140 g of potassium hydroxide was dissolved in 100 ml of water, and 600 ml of methanol was added slowly thereto while keeping the temperature at 20 °C using an ice bath, followed by adding 100 g of lovastatin thereto at 20 °C. The mixture was refluxed using an oil bath for 8 hours, and 150 ml of water was added thereto. Subsequently, methanol was removed under a reduced pressure, and 550 ml of water and 300 ml of diethylether were added thereto. The mixture was acidified by slowly adding 6N-HCl at 5 to 10 °C with stirring, and stirred for additional 30 minutes at the same temperature. The resulting precipitates were filtered, washed with a mixture of water and diethylether, and dried, to obtain 82 g of the title compound as a white solid(yield: 98%, purity: 98.6%).

20

m.p.: 128 °C

¹H-NMR(δ , CDCl₃): 5.98(d, 1H), 5.80(dd, 1H), 5.54(bs, 1H), 4.33(m, 1H), 4.28(m, 1H), 3.98(m, 1H), 2.51(bs, 2H), 1.18(d, 3H), 0.90(d, 3H)

- 25 Example 2: Preparation of 6(R)-[2-(8'(S)-hydroxy-2'(S),6'(R)-dimethyl-1',2',6',7',8',8a'(R)-hexahydronaphthyl-1'(S))ethyl]-4(R)-hydroxy-3,4,5,6-tetrahydro-2H-pyran-2-one(the compound of formula (IV))

79 g of 7-[1',2',6',7',8',8a'(R)-hexahydro-2'(S),6'(R)-dimethyl-8'(S)-hydroxy-1'(S)-naphthyl]-3(R),5(R)-dihydroxy heptanoic acid prepared in Example 1 was dissolved in 560 ml of ethyl acetate, and 0.8 g of p-toluene sulfonic acid was added thereto. The reaction mixture was stirred at room temperature for 3 hours, followed by addition of 700 ml of hexane, and stirred for additional 30 minutes. The resulting precipitates were then filtered, washed with 100 ml of hexane, and dried, to obtain 73.5 g of the title compound as a white solid(yield: 98%, purity: 98.2%).

10 m.p.: 125-126 °C

¹H-NMR(δ , CDCl₃): 6.0(d, 1H), 5.80(dd, 1H), 5.54(bs, 1H), 4.72(m, 1H), 4.38(m, 1H), 4.23(bs, 1H), 2.68(dd, 2H), 2.39(m, 2H), 2.15-1.78(m, 9H), 1.58-1.18(m, 4H), 1.19(d, 3H), 0.90(m, 1H)

15 Example 3: Preparation of 6(R)-[2-(8'(S)-hydroxy-2'(S),6'(R)-dimethyl-1',2',6',7',8',8a'(R)-hexahydronaphthyl-1'(S))ethyl]-4(R)-(dimethyl-tert-butyl silyloxy)-3,4,5,6-tetrahydro-2H-pyran-2-one (the compound of formula (V))

70 g of 6(R)-[2-(8'(S)-hydroxy-2'(S),6'(R)-dimethyl-1',2',6',7',8',8a'(R)-hexahydronaphthyl-1'(S))ethyl]-4(R)-hydroxy-3,4,5,6-tetrahydro-2H-pyran-2-one prepared in Example 2 was dissolved in 800 ml of dichloromethane, and 43 g of imidazole and 43 g of t-butyl dimethylchlorosilane were successively added thereto. The reaction mixture was stirred at 25 to 30 °C for 6 hours, and washed successively three times with 300 ml of water, 200 ml of 0.2 N-HCl, 25 100 ml of saturated sodium bicarbonate and 100 ml of saturated saline. The organic layer was then separated, dried over anhydrous MgSO₄, filtered and the solvent was removed. 300 ml of hexane was added to the resulting solid, and

stirred at room temperature for 30 minutes. The resulting precipitates were filtered, and dried, to obtain 87.6 g of the title compound as a white solid(yield: 96%, purity: 98.5%).

5 m.p.: 134-136 °C

¹H-NMR(δ , CDCl₃): 6.03(d, 1H), 5.78(dd, 1H), 5.57(m, 1H), 4.70(m, 1H), 4.28(m, 2H), 2.58(d, 2H), 1.19(d, 3H), 0.90(s, 9H), 0.89(d, 3H). 0.1(s, 6H)

Example 4: Preparation of 6(R)-[2-(8'(S)-2",2"-dimethylbutyryloxy-
10 2'(S),6'(R)-dimethyl-1',2',6',7'.8',8a'(R)-hexahydronaphthyl-1'(S))ethyl]-
4(R)-(dimethyl-tert-butylsilyloxy)-3,4,5,6-tetrahydro-2H-pyran-2-one(the
compound of formula (VI))

15 10 g of benzyltri-n-butylammonium bromide and 2.3 ml of pyridine were added to 100 ml of benzene. The mixture was refluxed for 30 minutes using a Dean- stark trap, followed by addition of 5.2 ml of 2,2-dimethylbutyryl chloride and 10 g of 6(R)-[2-(8'(S)-hydroxy-2'(S),6'(R)-dimethyl-1',2',6',7'.8',8a'(R)-hexahydronaphthyl-1'(S))ethyl]-4(R)-(dimethyl-tert-butylsilyloxy)-3,4,5,6-tetrahydro-2H-pyran-2-one prepared in Example 3, 20 refluxed for additional 8 hours, and then cooled. The resulting mixture was diluted with 300 ml of diethyl ether, and washed successively twice with 300 ml of water, 100 ml of 0.2N-HCl and 200 ml of saturated sodium bicarbonate. The organic layer was then separated, dried over anhydrous MgSO₄ and filtered. Evaporation of the solvent gave 12.1 g of the title compound as an oil(yield: 25 98%, purity: 98.3%).

¹H-NMR(δ , CDCl₃): 6.01(d, 1H), 5.80(dd, 1H), 5.52(bs, 1H), 5.35(bs, 1H),

4.60(m, 1H), 4.30(t, 2H), 2.60(m, 2H), 2.38(m, 2H), 2.20(d, 1H). 1.98-1.25(m, 14H), 1.12(d, 3H), 1.10(d, 3H), 0.95-0.81(m, 15H), 0.1(s, 6H)

Example 5: Preparation of 6(R)-[2-(8'(S)-2",2"-dimethylbutyryloxy-5'2'(S),6'(R)-dimethyl-1',2',6',7',8',8a'(R)-hexahydronaphthyl-1'(S)ethyl]-4(R)-hydroxy-3,4,5,6-tetrahydro-2H-pyran-2-one(the compound of formula (I))

12.3 g of 6(R)-[2-(8'(S)-2",2"-dimethylbutyryloxy-2'(S),6'(R)-dimethyl-1',2',6',7',8',8a'(R)-hexahydronaphthyl-1'(S)ethyl]-4(R)-(dimethyl-10 tert-butyl silyloxy)-3,4,5,6-tetrahydro-2H-pyran-2-one prepared in Example 4 was dissolved in 100 ml of tetrahydrofuran, and 5 ml of acetic acid and 63 ml of 1N-tetrabutyl ammonium fluoride were successively added thereto. The mixture was stirred at room temperature for 48 hours, diluted with 800 ml of diethylether, and washed successively twice with 150 ml of water, 150 ml of 15 0.2N-HCl, 150 ml of water, 150 ml of saturated sodium bicarbonate and 150 ml of saturated saline. The organic layer was then separated, dried over anhydrous MgSO₄ and filtered. Evaporation of the solvent gave a crude product, which was recrystallized from ethyl acetate/hexane to obtain 8.8 g of the title compound as a white solid(yield: 91%, purity: 99.2%).

20

m.p.: 133-135 °C

¹H-NMR(δ , CDCl₃): 6.0(d, 1H), 5.78(dd, 1H), 5.51(bs, 1H), 5.37(m, 1H), 4.62(m, 1H), 4.39(bs, 1H), 2.92(m, 1H), 2.64-2.74(m, 2H), 2.4(m, 1H). 1.13(s, 6H), 0.86(t, 3H)

25


As shown above, the method of the present invention is capable of providing highly pure simvastatin in a high yield, at cost lower than the

conventional methods.


While the invention has been described with respect to the specific embodiments, it should be recognized that various modifications and changes may be made by those skilled in the art to the invention which also fall within
5 the scope of the invention as defined as the appended claims.



What is claimed is :

1. A method of preparing simvastatin of formula (I) comprising the steps of:
 - (a) treating lovastatin of formula (II) with potassium hydroxide dissolved in a mixture of water and methanol to obtain the compound of formula (III);
 - 5 (b) relactonizing the compound of formula (III), and protecting the hydroxy group on the lactone ring to obtain the compound of formula (V); and
 - (c) acylating the compound of formula (V) with 2,2-dimethylbutyryl chloride or 2,2-dimethylbutyryl bromide in the presence of an acylation catalyst which is a compound of formula (VII) or a compound of formula (VIII) in an organic solvent, followed by removing the silyl protecting group on the lactone ring to obtain simvastatin of formula (I).
- 10



15





$$_5 \quad (\text{R}^1)_3\text{R}^2\text{N}^+\text{X}^- \quad (\text{VII})$$

$$(R^1)_3R^2P^+X^- \quad (VIII)$$

Wherein R¹ is C₁₋₂₀ alkyl or phenyl; R² is C₁₋₂₀ alkyl, phenyl, or benzyl; and X is Br or I.

2. The method of claim 1, wherein potassium hydroxide used in step (a) is employed in an amount ranging from 5 to 15 equivalents based on the amount of lovastatin of formula (II).

15

3. The method of claim 1, wherein water and methanol are used in a ratio (v:v) of 1:2 to 1:20 in step (a).

4. The method of any one of claims 1 to 3, wherein the mixture of water and methanol is used in step (a) in an amount of 1 to 8 ml per 1 g of potassium hydroxide
5. The method of claim 1, wherein the acylation catalyst used in step (c) is selected from the group consisting of benzyltri-n-butylammonium bromide, tetra-n-butylammonium bromide and tetra-n-butylphosphonium bromide.
6. The method of claim 1 or 5, wherein the acylation catalyst used in step (c) is employed in an amount ranging from 0.5 to 3 equivalents based on the amount of the compound of formula (V).
7. The method of claim 1, wherein 2,2-dimethylbutyryl chloride or bromide used in step (c) is employed in an amount ranging from 1 to 3 equivalents based on the amount of the compound of formula (V).
8. The method of claim 1, wherein the acylation step (c) is carried out in refluxing benzene while azotropically removing water using a Dean- stark trap.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/KR02/02434

A. CLASSIFICATION OF SUBJECT MATTER

IPC7 C07D 309/06

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC7 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
Korean Patents and Applications for inventions since 1975Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
CAPLUS(STN), CASREACT(STN)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 2001/00606 A1(KANEKA CORPORATION) 04 JANUARY 2001, SEE THE WHOLE DOCUMENT	1 - 8
A	WO 2001/30773 A2(MERCK Co., Inc.) 03 MAY 2001, SEE THE WHOLE DOCUMENT	1, 2
A	WO 2001/45484 A2(CHONG KUN DANG PHARMACEUTICAL CORP.,) 28 JUNE 2001, SEE THE WHOLE DOCUMENT	1 - 3, 5
A	US 5939564 A(RANBAXY LABORATORIES LIMITED) 17 AUGUST 1999, SEE ABSTRACT, EXAMPLES AND CLAIMS	1

 Further documents are listed in the continuation of Box C. See patent family annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier application or patent but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

28 MARCH 2003 (28.03.2003)

Date of mailing of the international search report

28 MARCH 2003 (28.03.2003)

Name and mailing address of the ISA/KR



Korean Intellectual Property Office
920 Dunsan-dong, Seo-gu, Daejeon 302-701,
Republic of Korea

Facsimile No. 82-42-472-7140

Authorized officer

WON, Ho Joon

Telephone No. 82-42-481-5605



INTERNATIONAL SEARCH REPORT

Information on patent family members

Int'l'

PCT/KR02/02434

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2001/00606 A1	04. 01. 2001	CA 2342361 AA EP 1110959 A1	04. 01. 2001 27. 06. 2001
WO 2001/30773 A2	03. 05. 2001	US 6380401 B1 EP 1228057 A2 US 6525205 B2	30. 04. 2002 07. 08. 2002 25. 02. 2003
WO 2001/45484 A2	28. 06. 2001	AU 2001-37752 A5	03. 07. 2001
US 5939564 A	17. 08. 1999	NONE	